Mystery Solved? GenSight’s Gene Therapy Does Move Between Eyes
Company hopes to file in Europe next year
Company boosted by animal study which helps answer riddle of improvement in untreated eye.
You may also be interested in...
Phase III success at 96 weeks sets up GenSight blindness therapy for EU filing, but puzzle of placebo arm benefits remain
The German biotech has developed its COVID-19 vaccine in record-breaking time, but artificial intelligence could help accelerate drug discovery over the longer term.
Russia is promising the best of both worlds – a low price with a near-perfect efficacy. While the basic science is plausible, its best-in-class claims are bound to generate skepticism.